Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, Bernstein ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want ...

Wall Street’s top analyst upgrades/downgrades from earnings season: Amgen, Chevron, P&G, Netflix, Applied Materials, Datadog ...

According to Benzinga Pro, Amgen Inc's peer group average for short interest as a percentage of float is 7.24%, which means ...

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In addition to DBS, Amgen also received a Buy from Piper Sandler’s David Amsellem in a report issued on January 20. However, on the same day, Bernstein downgraded Amgen (NASDAQ: AMGN) to a Hold.

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look ...

Amgen Inc (AMGN) reached a significant milestone as its stock hit a 52-week high of $346.41. This marks a notable point for the biotechnology company, reflecting a positive trend over the past year.

In a report released yesterday, Courtney Breen from Bernstein downgraded Amgen to a Hold, with a price target of $335.00. According to TipRanks, Breen is a 4-star analyst with an average return of 18.